Preclinical Evaluation of Lipid-Based Nanosystems
The use of lipid-based nanosystems, including lipid nanoparticles (solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC)), nanoemulsions, and liposomes, among others, is widespread. Several researchers have described the advantages of different applications of these nanosystems. Fo...
Saved in:
| Other Authors: | , |
|---|---|
| Format: | Book Chapter |
| Published: |
Basel, Switzerland
MDPI - Multidisciplinary Digital Publishing Institute
2021
|
| Subjects: | |
| Online Access: | Get Fullteks DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| LEADER | 05832naaaa2201441uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_76594 | ||
| 005 | 20220111 | ||
| 020 | |a books978-3-0365-1549-6 | ||
| 020 | |a 9783036515502 | ||
| 020 | |a 9783036515496 | ||
| 024 | 7 | |a 10.3390/books978-3-0365-1549-6 |c doi | |
| 041 | 0 | |a English | |
| 042 | |a dc | ||
| 072 | 7 | |a TB |2 bicssc | |
| 100 | 1 | |a Silva, Ana Catarina |4 edt | |
| 700 | 1 | |a Sousa Lobo, José Manuel |4 edt | |
| 700 | 1 | |a Silva, Ana Catarina |4 oth | |
| 700 | 1 | |a Sousa Lobo, José Manuel |4 oth | |
| 245 | 1 | 0 | |a Preclinical Evaluation of Lipid-Based Nanosystems |
| 260 | |a Basel, Switzerland |b MDPI - Multidisciplinary Digital Publishing Institute |c 2021 | ||
| 300 | |a 1 electronic resource (351 p.) | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a The use of lipid-based nanosystems, including lipid nanoparticles (solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC)), nanoemulsions, and liposomes, among others, is widespread. Several researchers have described the advantages of different applications of these nanosystems. For instance, they can increase the targeting and bioavailability of drugs, improving therapeutic effects. Their use in the cosmetic field is also promising, owing to their moisturizing properties and ability to protect labile cosmetic actives. Thus, it is surprising that only a few lipid-based nanosystems have reached the market. This can be explained by the strict regulatory requirements of medicines and the occurrence of unexpected in vivo failure, which highlights the need to conduct more preclinical studies.Current research is focused on testing the in vitro, ex vivo, and in vivo efficacy of lipid-based nanosystems to predict their clinical performance. However, there is a lack of method validation, which compromises the comparison between different studies.This book brings together the latest research and reviews that report on in vitro, ex vivo, and in vivo preclinical studies using lipid-based nanosystems. Readers can find up-to-date information on the most common experiments performed to predict the clinical behavior of lipid-based nanosystems. A series of 15 research articles and a review are presented, with authors from 15 different countries, which demonstrates the universality of the investigations that have been carried out in this area. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Technology: general issues |2 bicssc | |
| 653 | |a nanostructured lipid carriers (NLC) | ||
| 653 | |a formulation optimization | ||
| 653 | |a rivastigmine | ||
| 653 | |a quality by design (QbD) | ||
| 653 | |a nasal route | ||
| 653 | |a nose-to-brain | ||
| 653 | |a N-alkylisatin | ||
| 653 | |a liposome | ||
| 653 | |a urokinase plasminogen activator | ||
| 653 | |a PAI-2 | ||
| 653 | |a SerpinB2 | ||
| 653 | |a breast cancer | ||
| 653 | |a liposomes | ||
| 653 | |a target delivery nanosystem | ||
| 653 | |a FZD10 protein | ||
| 653 | |a colon cancer therapy | ||
| 653 | |a supersaturation | ||
| 653 | |a silica-lipid hybrid | ||
| 653 | |a spray drying | ||
| 653 | |a lipolysis | ||
| 653 | |a lipid-based formulation | ||
| 653 | |a fenofibrate | ||
| 653 | |a mesoporous silica | ||
| 653 | |a oral drug delivery | ||
| 653 | |a hyaluronic acid | ||
| 653 | |a drug release | ||
| 653 | |a light activation | ||
| 653 | |a stability | ||
| 653 | |a mobility | ||
| 653 | |a biocorona | ||
| 653 | |a dissolution enhancement | ||
| 653 | |a phospholipids | ||
| 653 | |a solid dosage forms | ||
| 653 | |a porous microparticles | ||
| 653 | |a nanoemulsion(s) | ||
| 653 | |a phase-behavior | ||
| 653 | |a DoE | ||
| 653 | |a D-optimal design | ||
| 653 | |a vegetable oils | ||
| 653 | |a non-ionic surfactants | ||
| 653 | |a efavirenz | ||
| 653 | |a flaxseed oil | ||
| 653 | |a nanostructured lipid carriers | ||
| 653 | |a nanocarrier | ||
| 653 | |a docohexaenoic acid | ||
| 653 | |a neuroprotection | ||
| 653 | |a neuroinflammation | ||
| 653 | |a fluconazole | ||
| 653 | |a Box‒Behnken design | ||
| 653 | |a nanotransfersome | ||
| 653 | |a ulcer index | ||
| 653 | |a zone of inhibition | ||
| 653 | |a rheological behavior | ||
| 653 | |a ex vivo permeation | ||
| 653 | |a nanomedicine | ||
| 653 | |a cancer | ||
| 653 | |a doxorubicin | ||
| 653 | |a melanoma | ||
| 653 | |a drug delivery | ||
| 653 | |a ultrasound contrast agents | ||
| 653 | |a phospholipid coating | ||
| 653 | |a ligand distribution | ||
| 653 | |a cholesterol | ||
| 653 | |a acoustic response | ||
| 653 | |a microbubble | ||
| 653 | |a lipid phase | ||
| 653 | |a dialysis | ||
| 653 | |a ammonia | ||
| 653 | |a intoxication | ||
| 653 | |a cyanocobalamin | ||
| 653 | |a vitamin B12 | ||
| 653 | |a atopic dermatitis | ||
| 653 | |a psoriasis | ||
| 653 | |a transferosomes | ||
| 653 | |a lipid vesicles | ||
| 653 | |a skin topical delivery | ||
| 653 | |a oligonucleotide | ||
| 653 | |a self-emulsifying drug delivery systems | ||
| 653 | |a hydrophobic ion pairing | ||
| 653 | |a intestinal permeation enhancers | ||
| 653 | |a Caco-2 monolayer | ||
| 653 | |a clarithromycin | ||
| 653 | |a solid lipid nanoparticles | ||
| 653 | |a optimization | ||
| 653 | |a permeation | ||
| 653 | |a pharmacokinetics | ||
| 653 | |a follicular targeting | ||
| 653 | |a dexamethasone | ||
| 653 | |a alopecia areata | ||
| 653 | |a lipomers | ||
| 653 | |a lipid polymer hybrid nanocapsules | ||
| 653 | |a biodistribution | ||
| 653 | |a skin | ||
| 653 | |a ethyl cellulose | ||
| 653 | |a n/a | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/4039 |7 0 |z Get Fullteks |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/76594 |7 0 |z DOAB: description of the publication |